About the BALANCE Study
It is estimated that one in five Americans are affected by allergic rhinitis, an inflammatory disease characterized by symptoms such as sneezing, nasal itch, runny nose and nasal congestion. The BALANCE Research Study looks at the real world use of QNASL among 750 patients at study centers across the United States.
Asthma and Allergy Foundation of America, Allergy Facts and Figures, www.aafa.org
Participants who qualify for the BALANCE Study:
- Receive QNASLTM Nasal Aerosol based on standard clinical procedure
- Are asked to follow the recommended dose of QNASLTM Nasal Aerosol (beclomethasone diproprionate), as prescribed by their doctor
- Complete brief, online surveys approximately every 30 days for up to 12 months, at home or at other locations with internet access
- Receive payment each time the online survey is completed
Do you think you may qualify for the BALANCE Study? Click here for a list of BALANCE Study clinics
QNASLTM Nasal Aerosol is an FDA-approved prescription corticosteroid medication that treats seasonal and year-round nasal allergy symptoms in adults and adolescents 12 years of age and older. Please see the Full Prescribing Information for more details about QNASLTM.
Important Safety Information